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doi:10.101Influence of Pretransplantation Serum Ferritin on
Nonrelapse Mortality after Myeloablative and
Nonmyeloablative Allogeneic Hematopoietic Stem
Cell Transplantation
Keisuke Kataoka,1 Yasuhito Nannya,1 Akira Hangaishi,1 Yoichi Imai,1 Shigeru Chiba,2
Tsuyoshi Takahashi,1 Mineo Kurokawa1,2Iron overload might be an important contributor to nonrelapse mortality (NRM) in hematopoietic stem cell
transplantation (HSCT). We studied 264 patients undergoing allogeneic HSCT for hematologic malignancies
between 1996 and 2006, using pretransplantation serum ferritin as a surrogate marker of iron overload. At
5 years, patients in the high ferritin group ($599 ng/mL) had a lower overall survival (OS; 33.0% versus 63.5%;
P\.001) and a higher NRM (34.9% versus 13.7%; P\.001) than those in the low ferritin group (\599 ng/mL).
Multivariate analyses showed that high pretransplantation serum ferritin was a significant risk factor for
worse survival (relative risk [RR] 5 1.68; P 5 .05) and increased NRM (RR 5 2.47; P 5 .01). There was
no significant difference in the cumulative incidence of relapse, and acute and chronic graft-versus-host dis-
ease (aGVHD, cGVHD) between the 2 groups. Patients in the high ferritin group were more likely to die of
infection (P\.010) and organ failure (P\.019). Similar results were observed after dividing the patients ac-
cording to the intensity of conditioning regimens. These findings emphasize the prognostic impact of pre-
transplantation serum ferritin in HSCT recipients.
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Hematologic malignancy, Hematopoietic cell transplantation-specific comorbidity indexINTRODUCTION
Ironoverload is common inpatients undergoing al-
logeneic hematopoietic stem cell transplantation
(HSCT) for hematologic disorders [1-15]. Several
studies have reported the association between iron
overload and transplant complications such as chronic
liver disease [4-7,13,14,16-18], sinusoidal obstruction
syndrome [13,14,19], infection [11-14,20-25], and idi-
opathic pneumonia syndrome [13].The adverse impact
of iron overload on survival of patients undergoing al-
logeneicHSCT for thalassemia is well established [26].1Department of Hematology & Oncology, Graduate
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6/j.bbmt.2008.11.012However, very few studies have assessed the role of iron
overload in the outcome of allogeneic HSCT for other
hematologic disorders. Previous studies showed that an
elevated pretransplantation serum ferritin level, a sur-
rogate marker of iron overload, was associated with
lower overall survival (OS) and increased nonrelapse
mortality (NRM) in patients undergoingmyeloablative
allogeneicHSCT for hematologicmalignancies [9,10].
In general, the main causes of NRM after allogeneic
HSCT are infection and graft-versus-host disease
(GVHD). However, little is known about the causes
of NRM, and the incidence of acute and chronic
GVHD (aGVHD, cGVHD) in these patients.
Nonmyeloablative HSCT represents an effective
strategy to reduce the toxicity of transplantation, as
was shown in patients with older age or organ dysfunc-
tionwith hematologicmalignancies [27].However, it is
not clear whether the adverse impact of iron overload is
present in nonmyeloablative HSCT.
The aims of this study were: (1) to determine the
impact of pretransplantation serum ferritin on trans-
plant outcome in patients undergoing allogeneic
HSCT for hematologic malignancies; (2) to identify
the causes of NRM in patients with elevated ferritin
values; (3) to clarify the incidence of aGVHD and195
196 Biol Blood Marrow Transplant 15:195-204, 2009K. Kataoka et al.cGVHD in patients with high ferritin values, and (4) to
examine whether this association of pretransplantation
serum ferritin and transplant outcome is present in
nonmyeloablative HSCT.
METHODS
Patients
We retrospectively studied 272 consecutive adult
patients ($16 years old) with hematologic malignan-
cies who underwent allogeneic HSCT at the Univer-
sity of Tokyo Hospital, Japan, between June 1996
and October 2006. Two hundred sixty-four patients
were included in the present study, as 8 patients were
excluded because of the lack of data.
Myeloablative conditioning regimens included
either total body irradiation (TBI)-based regimens
or non-TBI-based regimens. TBI-based regimens
mainly consisted of cyclophosphamide (Cy; 60 mg/
kg/day for 2 days) plus fractionated TBI (12 Gy),
whereas non-TBI-based regimens busulfan (Bu; 1
mg/kg every 6 hours for 4 days) plus Cy (60 mg/kg/
day for 2 days). Patients were offered nonmyeloablative
conditioning regimens as they were ineligible for con-
ventional HSCTbecause of (1) age$56 years (n5 24);
(2) presence of preexisting significant medical problem
(severe cardiac dysfunction [n5 3], serious respiratory
failure [n 5 2], invasive pulmonary aspergillosis [n 5
1]); and (3) history of high-dose HSCT (n 5 10; 4 pa-
tients were also old, and 2 patients also had significant
medical problems). Nonmyeloablative conditioning
regimens consisted of fludarabine (Flu)-based regi-
mens with or without low-dose TBI (4 Gy).
Prophylaxis for GVHD was performed with calci-
neurin inhibitors (cyclosporine [CsA] or tacrolimus)
with or without short-term methotrexate (sMTX) in
most patients. In vivo T cell depletion using alemtuzu-
mab was performed in 30 patients, concomitant with
CsA and sMTX.
Human leukocyte antigen (HLA)-matching for do-
nor selection was based on serologic typing forHLA-A
and -B antigens, andmolecular typing for HLA-DRB1
antigen.
Disease morphology was determined according to
the French-American-British classification. Standard-
risk diseases were defined as acute leukemia in the first
or second complete remission, chronic myelogenous
leukemia (CML) in the first or second chronic phase,
chemosensitive lymphoma, and myelodysplastic syn-
drome (MDS) in refractory anemia (RA) or refractory
anemia with ringed sideroblasts (RARS). All the other
conditions were classified as high-risk diseases.
Prophylaxis against bacterial infection was per-
formedwith tosufloxacin, fungal infectionwith flucona-
zole, herpes simplex virus (HSV) infection with
acyclovir, and Pneumocystis jiroveci infection with sulfa-
methoxazole/trimethoprim.Pretransplantation comorbidities were assessed
retrospectively by comprehensive review of medical
records and computer database system according to
the hematopoietic cell transplantation-specific comor-
bidity index (HCT-CI) classification (44 missing data
of pulmonary diffusing capacity for carbon monoxide
and 3 missing data of whole pulmonary function tests)
[28]. Each patient was assigned a comorbidity score
and was stratified into low-risk (score 0), intermedi-
ate-risk (score 1-2), and high-risk (score $3) groups
based on their total score.
Information concerning Karnofsky performance
status was collected by a comprehensive review of
medical records and assessed as per the Karnofsky
scale. Karnofsky performance status scores were cate-
gorized as low (#80%) or high (.80%) in accordance
with previous reports [29].
Cause of death information was obtained from
detailed review of the patients’ medical charts and data-
base that routinely record the primary cause of death as
assigned by the treating physician at the time of patient
death in a uniform manner.
This study was performed in accordance with the
Helsinki Declaration and approved by the Ethics
Committee of the University of Tokyo Hospital. All
patients provided written informed consent.
Assessment of Iron Overload
Weused pretransplantation serum ferritin as a sur-
rogatemarker of iron overload at the time of transplan-
tation, because it is inexpensive, correlated with
directly measured liver iron content [30], and reliable,
with extensive clinical validation in monitoring iron
status [31]. Serum ferritin was routinely measured as
a part of routine pretransplant workup before the
beginning of the conditioning regimen by using fluo-
rescein enzyme immunoassay at our hospital. Because
ferritin reflects acute inflammatory reaction besides
iron overload, we included pretransplantation serum
CRP and albumin, which were measured at the same
time as serum ferritin and available in all of the studied
patients, in themultivariatemodels for adjusting the in-
fluence of inflammation.
Statistical Methods
The duration of follow-up was the time from
transplant to the last assessment for survivors. Vari-
ables related to the patients, the underlying diseases,
the transplantation procedures, and the causes of
NRM were compared between the groups with the
Fisher’s exact test for categoric variables and
the Mann-Whitney U-test for continuous variables
[32]. Probabilities of OS were calculated with the
Kaplan-Meier method; the log-rank test was used for
univariate comparisons [33]. For analyses of OS, death
from any cause was considered an event, and data on
Figure 1. OS after allogeneic HSCT for hematologic malignancies in
patients stratified by pretransplantation serum ferritin. *In the first quar-
tile, ferritin level was\182 ng/mL, the second quartile, 182-599 ng/mL,
the third quartile, 599-1178.5 ng/mL, and the fourth quartile, .1178.5
ng/mL. Compared with patients in the first quartile, those in the third
and fourth quartile had significantly inferior survival (P\ .001, each),
but those in the second quartile did not (P 5 .856).
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censored. Probabilities of NRM, relapse, and aGVHD
and cGVHDwere calculated with the use of the cumu-
lative-incidence-function method [34]. For NRM, re-
lapse was the competing event; for relapse, NRM was
the competing event; for GVHD, death without
GVHD was the competing event. Data on patients
who were alive without an event were censored at the
last follow-up.
The association of pretransplantation serum ferri-
tin and the transplant outcomes was evaluated in mul-
tivariate analyses, with the use of Cox proportional-
hazards regression to adjust for OS and Fine and
Gray’s proportional-hazards model for subdistribu-
tion of a competing risk for NRM [35]. The variables
considered in multivariate analyses were pretransplan-
tation serum ferritin, CRP, and albumin, age and sex of
recipients, type of hematologic malignancies, disease
status at transplantation, interval between diagnosis
and transplantation, type of grafts, HLA compatibility,
conditioning regimen, prophylaxis against GVHD,
year of transplantation, history of prior transplanta-
tion, donor-recipient sex mismatch, HCT-CI, and
KPS. Pretransplantation serum ferritin was coded ac-
cording to whether it exceeds the median values. Pre-
transplantation serum CRP and albumin were coded
according to whether they were normal or not. The
relative risk estimates with their 95% confidence inter-
vals and respective P values were reported from these
analyses. All P values are 2-sided, with a type I error
rate fixed at 0.05. Statistical analyses were performed
with R 2.6.1 software (The R Foundation for Statisti-
cal Computing, 2007).RESULTS
Patients
We reviewed the records of 264 adult patients who
underwent allogeneic HSCT for hematologic malig-
nancies at our institution.Themedian value of pretrans-
plantation serum ferritin was 599 ng/mL (range: 5-8128
ng/mL). There was a strong relationship between pre-
transplantation serum ferritin and OS (Figure 1). The
5-year OS for patients with pretransplantation ferritin
in the first quartile (\182 ng/mL)was 62.9% (95%con-
fidence interval [CI], 51.6%-76.8%); in the secondquar-
tile (182-599 ng/mL), 64.2% (95% CI, 52.2%-79.0%);
in the third quartile (599-1178.5 ng/mL), 40.3% (95%
CI, 29.4%-55.4%); and in the fourth quartile
(.1178.5 ng/mL), 23.7% (95% CI, 13.7%-40.9%).
Compared with patients in the first quartile, those in
the third and fourth quartile had a significantly inferior
OS (P\ .001, each), but those in the second quartile
did not (P 5 .856). The patients, thus, were divided
into 2 groups (ie, high ferritin group and low ferritingroup) according to themedian value of pretransplanta-
tion ferritin (ie, 599 ng/mL).
Their clinical characteristics are shown in Table 1.
One hundred two patients received grafts from
HLA-matched related donors, 77 patients from
matched unrelated donors, and 85 patients from mis-
matched related (n5 45) or unrelated (n5 40) donors.
Compared with patients in the low ferritin group,
patients in the high ferritin group were more likely to
be male, have acute myelogenous leukemia (AML) and
MDS, have high-risk diseases at transplantation, have
histories of prior transplantations, have high HCT-CI
scores, and have low KPS. Patients in the high ferritin
group were less likely to have CML and non-Hodgkin
lymphoma (NHL), and have received CsA and sMTX
as GVHD prophylaxis than those in the low ferritin
group. Median CRP and albumin were 0.30 mg/dL
(range: 0.02-17.20 mg/dL) and 4.0 g/dL (range: 2.3-
5.2 g/dL), respectively. The percentage of patients
with elevated serum CRP (.0.30 mg/dL) and lower
albumin (\3.9 g/dL) in the high ferritin group was
significantly higher than those in the low ferritin group.OS, NRM, and Relapse
Median follow-up period for survivors afterHSCT
was 48.9 months (range: 3.0-136.7 months). At 5 years,
patients in the high ferritin group had a significantly in-
ferior OS than those in the low ferritin group (33.0%
versus 63.5%; P\.001) (Figure 2A).Multivariate anal-
yses of risk factors among all patients showed that high
pretransplantation serum ferritin (relative risk [RR] 5
1.68; 95% CI, 1.01-2.78; P 5 .05), high-risk disease
(RR 5 3.25; 95% CI, 1.96-5.39; P \ .01), the use
of alemtuzumab (RR 5 3.41; 95% CI, 1.49-7.82;
P # .01), and high-risk HCT-CI (RR 5 1.75; 95%
Table 1. Clinical Characteristics of 264 Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hemato-
logic Malignancies According to Pretransplantation Serum Ferritin
Variable Total (N 5 264) Low ferritin < 599 ng/mL (N 5 132) High ferritin $599 ng/mL (N 5 132) P Value*
Age, years .082
Median 40 38 41
Range 16-66 16-62 18-66
Sex .003
Male 170 (64) 73 (55) 97 (73)
Female 94 (36) 59 (45) 35 (27)
Disease classification <.001
Acute myelogenous leukemia 78 (30) 16 (12) 62 (47)
Acute lymphoblactic leukemia 62 (23) 31 (23) 31 (23)
Chronic myelogenous leukemia 51 (19) 45 (34) 6 (5)
Myelodysplastic syndrome 34 (13) 14 (11) 20 (15)
RA/RARS 9 (3) 2 (2) 7 (5)
RAEB/RAEBT 21 (8) 12 (9) 9 (7)
CoL 4 (2) 0 (0) 4 (3)
Non-Hodgkin lymphoma 33 (13) 24 (18) 9 (7)
Others 6 (2) 2 (2) 4 (3)
Disease risk at transplantation† <.001
Standard 146 (55) 88 (67) 58 (44)
High 118 (45) 44 (33) 74 (56)
Interval between diagnosis and transplantation, months 1.000
Median 10.6 10.9 10.1
Range 1.8-202.3 2.4-173.4 1.8-202.3
Graft source .510
Bone marrow 168 (64) 89 (67) 79 (60)
Peripheral blood 85 (32) 39 (30) 46 (35)
Others 11 (4) 4 (3) 7 (5)
Donor type .348
Matched related donor 102 (39) 53 (40) 49 (37)
Matched unrelated donor 77 (29) 42 (32) 35 (27)
Mismatched donor 85 (32) 37 (28) 48 (36)
Conditioning regimen .099
Myeloablative 230 (87) 121 (92) 109 (82)
TBI-based regimen 190 (72) 97 (73) 93 (70)
Non-TBI-based regimen 40 (15) 24 (18) 16 (12)
Nonmyeloablative 34 (13) 11 (8) 23 (18)
TBI-based regimen 12 (5) 3 (2) 9 (7)
Non-TBI-based regimen 22 (8) 8 (6) 14 (11)
GVHD prophylaxis .028
Cyclosporine alone 11 (4) 2 (2) 9 (7)
Cyclosporine and methotrexate 201 (76) 110 (83) 91 (69)
Tacrolimus and methotrexate 24 (9) 9 (7) 15 (11)
Alemzutumab 28 (11) 11 (8) 17 (13)
Transplant year .122
1995-1998 43 (16) 25 (19) 18 (14)
1999-2002 113 (43) 61 (46) 52 (39)
2003-2006 108 (41) 46 (35) 62 (47)
Prior transplantation .005
243 (92) 128 (97) 115 (87)
>1 21 (8) 4 (3) 17 (13)
Sex pair (Donor-Recipient) .396
Female-male 67 (25) 30 (23) 37 (28)
Others 197 (75) 102 (77) 95 (72)
Hematopoietic cell transplantation specific comorbidity index <.001
Low (0) 84 (32) 54 (41) 30 (23)
Intermediate (1-2) 96 (36) 51 (39) 45 (34)
High ($) 84 (32) 27 (20) 57 (43)
Karnofsky performance status .001
>80 168 (64) 97 (73) 71 (54)
#80 96 (36) 35 (27) 61 (46)
C-reactive protein <.001
03 170 (64) 105 (80) 65 (49)
>0.3 94 (36) 27 (20) 67 (51)
Albumin <.001
$3.9 178 (67) 104 (79) 74 (56)
<3.9 86 (33) 28 (21) 58 (44)
RA indicates refractory anemia; RARS, refractory anemia with ringed sideroblasts; RAEB, refractory anemia with excess blasts; RAEBT, refractory ane-
mia with excess blasts in transformation; CMML, chronic myelomonocytic leukemia; TBI, total body irradiation; GVHD, graft-versus host disease.
*The Fisher’s exact test was used for categoric variables and the Mann-Whitney U-test for continuous variables.
†Standard-risk diseases were defined as acute leukemia in the first or second complete remission, chronic myelogenous leukemiin the first or second
chronic phase, chemosensitive lymphoma, and myelodysplastic syndrome in refractory anemia or refractory anemia with ringed sideroblasts. All the
other conditions were classified as high-risk diseases.
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Figure 2. OS (A), NRM (B), and relapse (C) rates after allogeneic HSCT for hematologic malignancies in patients divided by the median value of the
pretransplantation serum ferritin level. Patients in the high ferritin group had significantly lower OS and higher NRM than those in the low ferritin group
(P\.001, each). The relapse rate was similar between the 2 groups (P 5 .137).
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OS (Table 2).
At 5 years, patients in the high ferritin group had
a significantly higherNRMthan those in the low ferritin
group (34.9% versus 13.7%; P \ .001) (Figure 2B).
There was no statistical difference in relapse rate be-
tween the 2 groups of patients (34.4% versus 28.3%;
P 5 .137) (Figure 2C). In multivariate analyses, high
pretransplantation serum ferritin (RR 5 2.47; 95% CI,
1.21-5.07; P 5 .01), the use of alemtuzumab (RR 5
4.70; 95% CI, 1.19-18.58; P 5 .03), and intermediate-
risk (RR 5 4.04; 95% CI, 1.57-10.37; P \ .01) and
high-risk HCT-CI (RR 5 4.34; 95% CI, 1.64-11.52;
P \ .01) were the significant risk factors associated
with increased NRM (Table 2).aGVHD and cGVHD
The cumulative incidence of grade II, III, and IV
aGVHD was similar between the 2 groups of patients
(37.1% versus 42.4% for the patients in the high and
low ferritin group; P 5 .422). There was no statistical
difference in the incidence of extensive cGVHD be-
tween the 2 groups of patients (43.9% versus 40.4%;
P 5 .703).Causes of NRM
A total of 58 patients died from nonrelapse causes,
16 of 132 patients in the low ferritin group (12%) and
42 of 132 patients in the high ferritin group (32%). Ta-
ble 3 lists the causes of NRM according to pretrans-
plantation serum ferritin. Patients in the high ferritin
group were more likely to die of infection (P 5 .010)
and organ failure (P 5 .019), compared with those in
the low ferritin group.Outcomes after Nonmyeloablative Compared
with Myeloablative Conditioning
As the decreased OS was attributable to the in-
creased NRM in patients with elevated ferritin values
who underwent allogeneic HSCT for hematologic
malignancies, we aimed to investigate whether this re-
lationship is still present in nonmyeloablative HSCT.
After myeloablative HSCT, patients in the high ferri-
tin group had an inferior OS (38.5% versus 62.6%;
P\ .001), and a higher NRM (30.8% versus 13.8%; P
\ .001) at 5 years, compared with those in the low ferri-
tin group. However, there was no significant difference
in relapse rate (33.2%and28.8%;P5 .302) between the
2 groups. Similarly, after nonmyeloablative HSCT,
Table 2. Factors Associated with Overall Survival and Nonrelapse Mortality within 264 Patients Undergoing Allogeneic Hema-
topoietic Stem Cell Transplantation for Hematologic Malignancies: Multivariate Analysis
Overall Survival Nonrelapse Mortality
Variable RR (95%CI) P Value* RR (95%CI) P Value*
Ferritin
Low (<599 ng/mL) 1.00 1.00
High ($599 ng/mL) 1.68 (1.01-2.78) .05 2.47 (1.21-5.07) .01
Age
<50 years 1.00 1.00
$50 years 0.97 (0.55-1.69) .90 1.35 (0.56-3.23) .51
Sex
Male 1.00 1.00
Female 1.30 (0.78-2.14) .31 1.30 (0.54-3.10) .56
Disease classification
Acute myelogenous leukemia 1.00 1.00
Acute lymphoblastic leukemia 1.36 (0.78-2.36) .28 0.90 (0.38-2.18) .82
Chronic myelogenous leukemia 0.90 (0.46-1.78) .77 1.84 (0.70-4.84) .22
Myelodysplastic syndrome 0.56 (0.29-1.06) .07 1.97 (0.77-5.01) .15
Non-Hodgkin lymphoma 1.28 (0.62-2.62) .50 2.22 (0.91-5.42) .08
Others 1.35 (0.34-5.39) .67 1.45 (0.11-19.04) .78
Disease risk at transplantation
Standard 1 00 1 00
High 3.25 (1.96-5.39) <.01 1.22 (0.61-2.44) .58
Interval between diagnosis and transplantation
#10.6 months 1.00 1.00
>10.6 months 1.28 (0.83-1.98) .27 1.47 (0.75-2.80) .26
Graft source
Bone marrow 1.00 1.00
Peripheral blood 0.97 (0.51-1.84) .93 0.52 (0.18-1.50) .23
Others 1.73 (0.71-4.23) .23 1.88 (0.79-4.46) .15
Donor type
Matched related donor 1.00 1.00
Alternative donor 0.65 (0.37-1.14) .13 0.46 (0.20-1.05) .06
Conditioning regimen
Myeloablative 1.00 1.00
Nonmyeloablative 1.13 (0.52-2.46) .75 0.90 (0.29-2.82) .86
Total body irradiation
Non-TBI-based regimen 1.00 1.00
TBI-based regimen 1.06 (0.60-1.85) .84 1.68 (0.70-4.04) .25
GVHD prophylaxis
Cyclosporine-based 1.00 1.00
Tacrolimus-based 1.02 (0.51-2.02) .96 1.21 (0.37-3.92) .75
Alemzutumab 3.41 (1.49-7.82) <.01 4.70 (1.19-18.58) .03
Transplant year
1995-1998 1.00 1.00
1999-2002 1.20 (0.66-2.19) .55 1.10 (0.45-2.67) .84
2003-2006 1.10 (0.54-2.22) .80 0.76 (0.28-2.09) .59
Prior transplantation
0 1.00 1.00
$1 1.61 (0.85-3.06) .15 1.62 (0.53-4.96) .40
Sex pair (Donor-Recipient)
Female-male 1.00 1.00
Others 1.03 (0.65-1.63) .91 0.96 (0.47-1.97) .92
Hematopoietic cell transplantation specific comorbidity index
Low (0) 1.00 1.00
Intermediate (1-2) 1.71 (1.00-2.91) .05 4.04 (1.57-10.37) <.01
High ($3) 1.75 (1.02-2.99) .04 4.34 (1.64-11.52) <.01
Karnofsky performance status
>80 1.00 1.00
#80 0.89 (0.56-1.40) .60 0.86 (0.43-1.71) .66
C-reactive protein
#0.3 1.00 1.00
>0.3 1.45 (0.94-2.23) .10 1.88 (0.90-3.90) .09
Albumin
$3.9 1.00 1.00
<3.9 1.43 (0.90-2.28) .13 1.36 (0.71-2.61) .35
RR indicates relative risk; CI, confidence interval; GVHD, graft-versus host disease.
*Cox proportional-hazards regressionmodel was used for overall survival, and Fine and Gray’s proportional-hazards model for subdistribution of a com-
peting risk was used for continuous nonrelapse mortality.
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Table 3. Causes of Nonrelapse Death in 264 Patients Un-
dergoing Allogeneic Hematopoietic Stem Cell Transplantation
for Hematologic Malignancies According to Pretransplantation
Serum Ferritin
Variable
Total
(N 5 264)
Low ferritin
<599 ng/mL
(N 5 132)
High ferritin
$599 ng/mL
(N 5 132) P Value†
No. of Patients (%)*
Nonrelapse
mortality
58 (22) 16 (12) 42 (32)
GVHD 14 (5) 5 (4) 9 (7) .411
Infection‡ 25 (9) 6 (5) 19 (14) .010
Hemorrhage 2 (1) 1 (1) 1 (1) 1.000
Interstitial
pneumonia
5 (2) 2 (2) 3 (2) .663
Organ failure§ 10 (4) 1 (1) 9 (7) .019
Secondary
malignancy
1 (0) 1 (1) 0 (0) 1.000
Unknown 1 (0) 0 (0) 1 (1) 1.000
GVHD indicates graft-versus host disease.
*Percentages of patients in each group are shown in the parentheses.
Because of rounding, the percentages of respective nonrelapse causes
of death may not sum to the percentage of overall nonrelapse mortality.
†The Fisher’s exact test was used.
‡A comparable proportion of patients who died of infect, had grade II,
III, and IV acute GVHD/or extensive chronic GVHD; 5 out of 6 in the
low ferritin group and 11 out of 19 in the high ferritin group. Infections
in the low ferritin group were bacterial (n5 1), fungal (n5 3), and viral
(n5 2). Infections in the high ferritin group were bacterial (n5 10), fun-
gal (n 5 6), and viral (n 5 3).
§Organ failure was assigned when the specific cause of organ failure, in-
cluding infection, GVHD, hemorrhage, or veno-occlusive disease, is not
determined despite the appropriate wsorerep. Multiorgan failure was
assigned when two or more organ failure was attributable to death. Or-
gan failure in the low ferritin group included heart failure (n5 1). Organ
failure in the high ferritin group included heart failure (n 5 2) renal fail-
ure (n 5 3), hepatic failure (n 5 2), and multiorgan failure (n 5 2).
Biol Blood Marrow Transplant 15:195-204, 2009 201Influence of High Ferritin on NRM after HSCTpatients in the high ferritin group had an inferior OS
(7.0% versus 80.8%;P5 .002) (Figure 3A), and a higher
NRM (54.3% versus 9.1%; P\ .001) (Figure 3B) at 5
years, compared with those in the low ferritin group.
However, there was no significant difference in relapse
rates (39.1% versus 22.7%; P 5 .137) (Figure 3C) be-
tween the 2 groups. Thus, patients with elevated ferritin
values had decreased OS because of increased NRM af-
ter allogeneic HSCT, regardless of the intensity of con-
ditioning regimens.DISCUSSION
The current analysis extended previous reports on
the role of pretransplantation serum ferritin in alloge-
neic HSCT. In this study, we showed that an elevated
pretransplantation serum ferritin level was associated
with decreased OS and increased NRM in patients un-
dergoing allogeneicHSCT for hematologic malignan-
cies, consistent with previous observations [9,10].
Furthermore, to our knowledge, this is the first report
to clarify the causes of NRM and the incidence of
aGVHD and cGVHD in patients with high ferritin
values. Moreover, we showed that pretransplantationserum ferritin affected adversely the transplant out-
come as well in patients who received nonmyeloabla-
tive conditioning regimens.
Decreased OS in patients with high ferritin values
was attributable to increasedNRM.Among the various
causes that might explain NRM, infection and organ
failure were significantly more frequent in patients in
the high ferritin group than those in the low ferritin
group. These findings are consistent with the previous
reports on the association between iron overload and
transplant related complications, such as infection
[11-14,20-25] and chronic liver disease [4-7,13,14,16-
18] after HSCT. One explanation for these results is
that free radical iron, in a state of iron excess, can lead
to a pro-oxidant state by generating free radicals, which
could subsequently cause tissue injury and increase the
risk of transplant related complications [14]. Indeed,
a previous study showed the presence of catalytic iron
that increased oxidative damage to proteins in the
serum of children with acute lymphoblastic leukemia
(ALL) receiving high-dose MTX [36]. Furthermore,
iron is an essential cofactor for the growth of a number
of opportunistic bacteria and fungi and free iron can
also increase the susceptibility of patients to infections
through impairment of cellular immunity and inhibi-
tion of chemotaxis and phagocytosis [14].
We used the median value of pretransplantation
serum ferritin level (ie, 599 ng/mL) as the cutoff value
for dividing the patients into the 2 groups. Guidelines
on iron-chelation therapy for heavily transfused pa-
tients such as thalassemia, aplastic anemia (AA), and
MDS recommend that the patients with serum ferritin
levels higher than 1000-2500 ng/mL might benefit
from the treatment for iron overload [37-39]. We
showed that patients with moderately elevated serum
ferritin levels (599-1178.5 ng/mL) had inferior sur-
vival, compared with patients with normal (5-182 ng/
mL) and mildly elevated serum ferritin levels (182-
599 ng/mL) (Figure 1). This suggests that pretrans-
plantation serum ferritin has adverse effects at lower
level for HSCT recipients than transfused patients.
In patients undergoing allogeneic HSCT, the
main cause of NRM in patients with high ferritin
values was infection. This cause of death is quite differ-
ent from that in chronically transfused patients such as
thalassemia, in which iron overload associated cardio-
myopathy and liver fibrosis were among the leading
causes of death before the introduction of iron-
chelation therapy [31]. Possible explanation for this
difference is that patients undergoing allogeneic
HSCT for hematologic malignancies were more sus-
ceptible to infections than those receiving chronic
transfusions because of prolonged neutropenia and
breaks in the mucocutaneous barrier because of the
HSCT preparative regimens, cell-mediated and hu-
moral immunity defects, and impaired functioning of
the reticuloendothelial system [40]. Considering that
Figure 3. OS (A), NRM (B), and relapse (C) rates after allogeneic HSCT following nonmyeloablative conditioning in patients divided by themedian value
of the pretransplantation serum ferritin level. Patients in the high ferritin group had significantly lower OS (P 5 .002) and higher NRM (P\.001) than
those in the low ferritin group. The relapse rate was similar between the 2 groups (P 5 .137).
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high ferritin group was comparable with those in the
low ferritin group, elevated ferritin value might be
a risk factor for infection, independent of aGVHD
and cGVHD. Thus, these results indicated the signif-
icance of the prophylaxis and surveillance regimen for
infectious diseases to prevent iron overload related
complications in patients with high ferritin values
undergoing allogeneic HSCT.
Allogeneic HSCT following nonmyeloablative
conditioning has been performed for hemoglobinopa-
thies and reduced the transplant related complications
in heavily transfused patients [41]. We, however,
showed that the association of pretransplantation se-
rum ferritin and NRM was present as well in patients
undergoing nonmyeloablative HSCT. As patients
with elevated ferritin value had decreased OS and
increased NRM after allogeneic HSCT, regardless of
the intensity of conditioning regimens, intervention
for iron overload, including phlebotomy and iron-
chelation therapy, in the pre- and posttransplantation
setting may be important to reduce the morbidity and
mortality in these patients, as well as thalassemia
patients [42,43], and its feasibility and safety need to
be investigated in further study.This study had a number of limitations. (1) This
study was a retrospective, single-institution study. In
particular, it is difficult to assign, retrospectively, the
causes of death in the posttransplantation setting. Addi-
tional prospective multicenter studies are required to
confirm the true association between iron overload
and transplant outcomes. (2) Ferritin is an acute phase
reactant and is not the best indicator of iron overload.
However, ferritin is a useful noninvasive surrogate, be-
cause it is inexpensive, widely available, and reliable
with extensive clinical validation inmonitoring iron sta-
tus [31]. Furthermore, ferritin has a strong association
with hepatic iron concentration directly measured by
liver biopsy [30]. Moreover, several guidelines on iron
overload recommend serum ferritin as a diagnostic
tool of iron overload [37-39]. Although the influence
of inflammation could be adjusted by the inclusion of
CRP and/or albumin in the multivariate analyses, fur-
ther studies using more reliable methods for assessment
of body iron stores such as liver biopsy andmagnetic res-
onance imaging would be helpful [15,18]. (3) The pa-
tients included in this study were a heterogeneous
population who had various backgrounds and diseases,
and underwent various transplant procedures, although
these factors were adjusted in the multivariate analyses.
Biol Blood Marrow Transplant 15:195-204, 2009 203Influence of High Ferritin on NRM after HSCT(4) As the number of patients who received nonmyeloa-
blative conditioningwas limited,we could not performa
multivariate analysis of the nonmyeloablative subgroup
alone. Further studies with larger number of nonmye-
loablative transplants would be necessary to confirm
these results.
In conclusion, our findings indicate that patients
with an elevated pretransplantation serum ferritin level
had inferior survival because of increasedNRM,mainly
from infection and organ failure, in allogeneic HSCT.
Moreover, this association was observed as well in
patients who received nonmyeloablative HSCT. These
results emphasize the potential value of the treatment of
iron overload in the pre- and posttransplantation set-
ting. Different strategy from that for chronically trans-
fused patients might be needed for pretransplant
patients, because early intervention for iron overload
and judicious prophylaxis and surveillance regimens
for infections may be more important in allogeneic
HSCT. Further study to confirm these findings would
be helpful.ACKNOWLEDGMENTS
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